Evotec and Odyssey Therapeutics have announced a strategic AI-enabled research and development (R&D) partnership to explore new treatments for autoimmune and inflammatory diseases. This collaboration will focus on utilising Evotec’s data-driven discovery platform alongside its AI data science and advanced screening technologies. Evotec chief scientific officer Dr Cord Dohrmann said: “Drug discovery increasingly depends on the ability to integrate deep disease biology with advanced experimental and computational approaches to drug discovery. “This collaboration with Odyssey illustrates well Evotec’s strategy in applying integrated discovery platform technologies to complex disease areas where new approaches are urgently needed. This work will be conducted in collaboration with Niagen Bioscience’s wholly owned subsidiary, NAD Pharmaceuticals, which is focused on developing accelerated ageing and rare genetic disease therapies.